IP Library Granted Patent US 9,834,605
Granted Patent B2
US 9,834,605 · App. 14/576,448 · Granted Dec 5, 2017

Antibodies to human programmed death receptor PD-1

Inventors: Gregory John Carven (Maynard, MA); Hans Van Eenenneem (Nijmegen, NL); Gradus Johannes Dulos (Elst, NL)
Assignee: Merck Sharpe & Dohme B.V.
C07K16/2803C07K16/2818G01N33/57488G01N33/6869C07K2317/24C07K2317/565C07K2317/76C07K2317/92G01N2333/55G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,605
App. No.
14/576,448
Granted
Dec 5, 2017
Kind
B2
Abstract

Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.

Claims (13)

1. An isolated polynucleotide encoding an antibody or antibody fragment which binds to human programmed death receptor 1 (PD-1), wherein the antibody or antibody fragment comprises

a. three light chain CDRs having the amino acid sequences set forth in SEQ ID NOs:15, 16 and 17; and/or

b. three heavy chain CDRs having the amino acid sequences set forth in SEQ ID NOs: 18, 19 and 20.

2. The isolated polynucleotide of claim 1 , which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 21, 22, 23, 24, and 27.

3. An expression vector comprising the polynucleotide of claim 1 .

4. An isolated host cell comprising the expression vector of claim 3 .

5. A method of producing an antibody or antibody fragment that binds to human programmed death receptor 1 (PD-1) comprising:

a. culturing a host cell in culture medium, wherein the host cell comprises the polynucleotide of claim 1 and wherein the host cell is cultured under conditions wherein the antibody or antibody fragment is expressed; and

b. recovering the antibody or antibody fragment from the host cell or culture medium.

6. The isolated polynucleotide of claim 1 , wherein the antibody or antibody fragment comprises a light chain variable region comprising amino acid residues 20 to 130 of SEQ ID NO:32 and a heavy chain variable region comprising amino acid residues 20 to 139 of SEQ ID NO:30.

7. The isolated polynucleotide of claim 6 , wherein the antibody or antibody fragment comprises a light chain comprising amino acid residues 20 to 237 of SEQ ID NO:36 and a heavy chain comprising amino acid residues 20 to 466 of SEQ ID NO:31.

8. An expression vector comprising the polynucleotide of claim 6 .

9. An isolated host cell comprising the expression vector of claim 8 .

Assignments (4)
MERGER Recorded Oct 27, 2017
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 044309/0565 →
MERGER Recorded Oct 27, 2017
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 044748/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2017
From: CARVEN, GREGORY JOHN; VAN EENENNAAM, HANS; DULOS, GRADUS JOHANNES
To: N.V. ORGANON
Reel/Frame 043968/0813 →
MERGER Recorded Oct 27, 2017
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 043969/0170 →
Continuity (5)
Division 13719756 · Dec 19, 2012
Continuation 12663950
Provisional Application 60944583 · Jun 18, 2007
Related Publication 20150232555A1 · Aug 20, 2015
Related Publication 20160304606A9 · Oct 20, 2016